TABLE 3

Predicted in vivo inhibition of CYP2D6, CYP3A, CYP2C9, and CYP1A2 mediated metabolism by atomoxetine, N-desmethylatomoxetine, and 4-hydroxyatomoxetine in CYP2D6 extensive and poor metabolizer populations

Compound	Predicted Inhibition
Compound		CYP3A	CYP2D6	CYP2C9	CYP1A2
CYP2D6 extensive metabolizers
Atomoxetine	11%	54%	None^a	None^a
N-Desmethylatomoxetine	1.2%	5.3%	0.4%	0.1%
4-Hydroxyatomoxetine	0.01%	0.08%	None^a	None^a
Total predicted inhibition	12%	60%	0.4%	0.1%
CYP2D6 poor metabolizers
Atomoxetine	28%	NC	None^a	None^a
N-Desmethylatomoxetine	28%	NC	11%	2.3%
4-Hydroxyatomoxetine	0.002%	NC	None^a	None^a
Total predicted inhibition	56%	NC	11%	2.3%

NC, not calculated due to the lack of functional CYP2D6 in the PM population.
↵ a No significant inhibition in vitro was observed.